Patients with atherosclerotic cardiovascular disease (ASCVD) who have their Lp(a) measured are more likely to achieve recommended target LDL-C levels than those who do not have their Lp(a) measured, according to data from the PREVAIL study of Lp(a) testing in 55,427 patients with ASCVD in Australia.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
